Quick Answer
RECURSION PHARMACEUTICALS, INC. reported Total Revenue of $74.68 million for fiscal year 2025.
RECURSION PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $74.68M +26.9% |
$58.84M +32.0% |
$44.58M +11.9% |
$39.84M +291.5% |
$10.18M +156.9% |
$3.96M +70.8% |
| Revenue (ASC 606) | $74.68M +26.9% |
$58.84M +32.0% |
$44.58M +11.9% |
$39.84M +291.5% |
$10.18M +156.9% |
$3.96M +70.8% |
| Net Income | -$644.76M -39.1% |
-$463.66M -41.3% |
-$328.07M -37.0% |
-$239.48M -28.4% |
-$186.48M -114.3% |
-$87.01M -40.6% |
| Diluted EPS | -$1.44 +14.8% |
-$1.69 -7.0% |
-$1.58 -16.2% |
-$1.36 +8.7% |
-$1.49 +62.7% |
-$3.99 -39.0% |
| Total Assets | $1.47B +1.8% |
$1.45B +121.6% |
$653.70M -6.8% |
$701.29M +14.9% |
$610.35M +104.4% |
$298.58M |
| Cash and Equivalents | $743.29M +25.1% |
$594.35M +51.8% |
$391.56M -28.8% |
$549.91M +92.9% |
$285.12M +8.8% |
$262.13M |
| Stockholders Equity | $1.13B +9.3% |
$1.03B +123.3% |
$463.44M -4.6% |
$485.81M -10.5% |
$542.94M +363.2% |
-$206.29M -66.0% |
| R&D Expense | $475.27M +51.2% |
$314.42M +30.3% |
$241.23M +54.9% |
$155.70M +15.1% |
$135.27M +113.6% |
$63.32M +38.2% |
| Operating Income | -$648.13M -35.3% |
-$479.00M -36.8% |
-$350.06M -42.5% |
-$245.73M -34.4% |
-$182.78M -116.0% |
-$84.61M -35.5% |
| Shares Outstanding | 528.18M +33.1% |
396.80M +69.4% |
234.27M +22.6% |
191.02M +12.2% |
170.27M +663.1% |
22.31M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $5.17M | -80.2% | -73.1% |
| Revenue (ASC 606) | September 30, 2025 | $5.17M | -80.2% | -73.1% |
| Net Income | September 30, 2025 | -$162.25M | -69.3% | +5.6% |
| Diluted EPS | September 30, 2025 | -$0.36 | -5.9% | +12.2% |
| Total Assets | September 30, 2025 | $1.40B | +92.6% | +7.5% |
| Cash and Equivalents | September 30, 2025 | $659.84M | +54.3% | +25.7% |
| Stockholders Equity | September 30, 2025 | $1.05B | +99.6% | +13.9% |
| R&D Expense | September 30, 2025 | $121.06M | +62.3% | -5.9% |
| Operating Income | September 30, 2025 | -$172.20M | -75.1% | +2.3% |
| Shares Outstanding | September 30, 2025 | 491.80M | +71.9% | +13.6% |
- RECURSION PHARMACEUTICALS, INC. reported Total Revenue of $74.68 million for fiscal year 2025.
- RECURSION PHARMACEUTICALS, INC. showed an increase of +26.9% in Total Revenue compared to the prior fiscal year.
- RECURSION PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $74.68 million for fiscal year 2025.
- RECURSION PHARMACEUTICALS, INC. showed an increase of +26.9% in Revenue (ASC 606) compared to the prior fiscal year.
- RECURSION PHARMACEUTICALS, INC. reported Net Income of -$644.76 million for fiscal year 2025.
- RECURSION PHARMACEUTICALS, INC. showed a decrease of -39.1% in Net Income compared to the prior fiscal year.
- RECURSION PHARMACEUTICALS, INC. reported Diluted EPS of $1.44 per share (loss) for fiscal year 2025.
- RECURSION PHARMACEUTICALS, INC. showed an increase of +14.8% in Diluted EPS compared to the prior fiscal year.
- RECURSION PHARMACEUTICALS, INC. reported Total Assets of $1.47 billion for fiscal year 2025.
- RECURSION PHARMACEUTICALS, INC. showed an increase of +1.8% in Total Assets compared to the prior fiscal year.
- RECURSION PHARMACEUTICALS, INC. reported Cash and Equivalents of $743.29 million for fiscal year 2025.
- RECURSION PHARMACEUTICALS, INC. showed an increase of +25.1% in Cash and Equivalents compared to the prior fiscal year.
- RECURSION PHARMACEUTICALS, INC. reported Stockholders Equity of $1.13 billion for fiscal year 2025.
- RECURSION PHARMACEUTICALS, INC. showed an increase of +9.3% in Stockholders Equity compared to the prior fiscal year.
- RECURSION PHARMACEUTICALS, INC. reported R&D Expense of $475.27 million for fiscal year 2025.
- RECURSION PHARMACEUTICALS, INC. showed an increase of +51.2% in R&D Expense compared to the prior fiscal year.
- RECURSION PHARMACEUTICALS, INC. reported Operating Income of -$648.13 million for fiscal year 2025.
- RECURSION PHARMACEUTICALS, INC. showed a decrease of -35.3% in Operating Income compared to the prior fiscal year.
- RECURSION PHARMACEUTICALS, INC. reported Shares Outstanding of 528.18 million shares for fiscal year 2025.
- RECURSION PHARMACEUTICALS, INC. showed an increase of +33.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: